重症COVID-19肺炎合并大面积肺栓塞的溶栓治疗
本文报告1例既往健康的47岁男性重症COVID-19肺炎(RT-PCR确诊)病例,入院时已存在快速进展的ARDS(氧合指数175)和脓毒症,实验室检查示淋巴细胞减少、D-二聚体升高(7.7 μg/ml,正常0-0.5 μg/ml)。患者在ICU接受ARDS-net/俯卧位通气及经验性抗COVID治疗并整合预防性抗凝;住院第2天出现休克伴氧合恶化,床旁超声显示大血栓从右心房迁移至肺循环。遂给予静脉阿替普酶100 mg/2 h作为抢救治疗,患者顺利康复,第20天出院居家隔离并口服利伐沙班。作者认为溶栓可能对COVID-19大面积肺栓塞有关键治疗作用,但不应低估潜在出血风险,床旁超声在管理COVID-19难治性ARDS中有核心作用。
要点
- 重症COVID-19患者住院第2天出现休克伴氧合恶化时,床旁超声发现大血栓从右心房迁移至肺循环,提示大面积肺栓塞。
- 对COVID-19合并大面积肺栓塞,静脉阿替普酶100 mg/2 h作为抢救治疗,本例患者顺利康复并于第20天出院。
- 作者认为溶栓可能对COVID-19大面积肺栓塞有关键治疗作用,但潜在出血风险不应被低估。
- 作者认为床旁超声在COVID-19难治性ARDS的管理中具有核心作用。
- 目前尚无COVID-19大面积肺栓塞管理的指南。
适用人群与场景
- 既往健康的47岁男性,因重症COVID-19肺炎(RT-PCR确诊)入住ICU,入院时氧合指数175、合并脓毒症。
- 住院第2天出现休克伴氧合恶化、床旁超声示大血栓从右心房迁移至肺循环的大面积肺栓塞患者。
处置流程与药物剂量
- 第1天:在ICU予ARDS-net/俯卧位通气,并予经验性抗COVID治疗,整合预防性抗凝。
- 住院第2天出现休克伴氧合恶化后,床旁超声发现大血栓从右心房迁移至肺循环,遂给予静脉阿替普酶100 mg/2 h作为抢救治疗。
- 患者康复后第20天出院居家隔离,口服利伐沙班。
红旗征与不能漏的情况
- 住院第2天出现休克伴氧合恶化,床旁超声示大血栓从右心房迁移至肺循环,需按大面积肺栓塞抢救处理。
研究设计与关键结果
- 病例报告:1例47岁既往健康男性重症COVID-19肺炎患者,入院时氧合指数175,D-二聚体7.7 μg/ml(正常0-0.5 μg/ml),淋巴细胞减少。
- 住院第2天出现休克伴氧合恶化,床旁超声示大血栓从右心房迁移至肺循环,予静脉阿替普酶100 mg/2 h抢救溶栓后顺利康复,第20天出院居家隔离并口服利伐沙班。
证据类型、等级与局限
- 证据类型:病例报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为溶栓可能对COVID-19大面积肺栓塞有关键治疗作用,但潜在出血风险不应被低估。
- 作者认为床旁超声在COVID-19难治性ARDS的管理中具有核心作用。
- 原文指出目前尚无COVID-19大面积肺栓塞管理的指南。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: No guidelines exist for the management of massive pulmonary embolism (PE) in COVID-19. We present a COVID-19 patient with refractory acute respiratory syndrome (ARDS), and life-threatening PE who underwent successful thrombolysis.
CASE PRESENTATION: A previously healthy 47 year old male was admitted to our hospital due to severe COVID-19 pneumonia [confirmed by Real-Time-Polymerase-Chain-Reaction (RT-PCR)]. He had rapidly evolving ARDS [partial arterial pressure of oxygen to fractional inspired concentration of oxygen ratio: 175], and sepsis. Laboratory results showed lymphocytopenia, and increased D-dimer levels (7.7 μg/ml; normal: 0-0.5 μg/ml). The patient was treated in the intensive care unit. On day-1, ARDS-net/prone positioning ventilation, and empiric anti-COVID treatment integrating prophylactic anticoagulation was administered. On hospital day-2, the patient developed shock with worsening oxygenation. Point-of-care-ultrasound depicted a large thrombus migrating from the right atrium to the pulmonary circulation. Intravenous alteplase (100 mg over 2 h) was administered as rescue therapy. The patient made an uneventful recovery, and was discharged to home isolation (day-20) on oral rivaroxaban.
CONCLUSION: Thrombolysis may have a critical therapeutic role for massive PE in COVID-19; however the risk of potential bleeding should not be underestimated. Point-of-care ultrasound has a pivotal role in the management of refractory ARDS in COVID-19.
参考来源
- Alharthy A, Faqihi F, Papanikolaou J, et al. Thrombolysis in severe COVID-19 pneumonia with massive pulmonary embolism. Am J Emerg Med. 2020. PMID: 32763101. doi:10.1016/j.ajem.2020.07.068
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。